Galectin Therapeutics (GALT) Total Liabilities (2010 - 2026)

Galectin Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $146.0 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 19.88% year-over-year to $146.0 million; the TTM figure through Mar 2026 stood at $146.0 million (up 19.88% YoY), while the FY2025 annual figure was $145.7 million, up 20.87% from the prior year.
• Total Liabilities was $146.0 million for Q1 2026 at Galectin Therapeutics, roughly flat from $145.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $146.0 million in Q1 2026 to a low of $39.8 million in Q1 2022.
• Historically, Total Liabilities has averaged $94.2 million across 5 years, with a median of $97.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 753.7% in 2022, then increased 12.34% in 2025.
• A 5-year view of Total Liabilities shows it stood at $53.5 million in 2022, then surged by 65.38% to $88.4 million in 2023, then jumped by 36.32% to $120.6 million in 2024, then increased by 20.87% to $145.7 million in 2025, then gained by 0.18% to $146.0 million in 2026.
• The last three Total Liabilities figures came in at $146.0 million (Q1 2026), $145.7 million (Q4 2025), and $136.4 million (Q3 2025), per Business Quant data.